

INOVIO BIOMEDICAL CORP  
Form 8-K  
July 09, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): July 8, 2008**

**Inovio Biomedical Corporation**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-14888**  
(Commission  
File Number)

**33-0969592**  
(I.R.S. Employer  
Identification No.)

**11494 Sorrento Valley Road, San Diego, California**  
(Address of principal executive offices)

**92121-1318**  
(Zip Code)

Registrant's telephone number, including area code: **(858) 597-6006**

**Not Applicable**

Former name or former address, if changed since last report

Edgar Filing: INOVIO BIOMEDICAL CORP - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On July 7, 2008, Inovio Biomedical Corporation (the registrant ) and VGX Pharmaceuticals, Inc., a privately-held Delaware corporation ( VGX ) executed a definitive merger agreement (the Merger Agreement ), which was announced via press release, as previously reported in the registrant s Current Report on Form 8-K filed July 8, 2008. On July 8, 2008, the registrant and VGX held a joint conference call, as also announced in the July 7, 2008 press release, to discuss the merger agreement and the anticipated transaction between the registrant and VGX. The transcript of the conference call and the slides presented during the conference call are filed as Exhibits 99.1 and 99.2 to this Report.

The registrant also notes that Dr. Avtar Dhillon s statement on page 5 of the conference call transcript that the parties anticipate that legacy Inovio equity interest holders and legacy VGX equity interest holders will share voting power over the combined company, 49% and 51% respectively, before completion of the 5.5 million of VGX convertible debt should have stated that the 49% and 51% voting power split was after completion of the expected automatic conversion of \$5.5 million of VGX convertible debt upon closing of the proposed merger.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

99.1 Transcript of July 8, 2008 Conference Call Held By Registrant and VGX  
99.2 Slides from July 8, 2008 Conference Call

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 9, 2008

INOVIO BIOMEDICAL CORPORATION

By: */s/ Peter Kies*  
Peter Kies, Chief Financial Officer